Samsung Electronics Co., Ltd.

The Catholic University of Korea Industry-Academic Cooperation Foundation

Curogen Technology Co., Ltd.

Catholic University Industry Academic Cooperation Foundation

The Catholic University of Korea Industry-Academic Cooperation Foundation, Catholic Univ. of Korea Songeui Campus

The Catholic University of Korea Industry-Academic Corporation Foundation

Min-Jung Park

Mi-La Cho

Seon-Yeong Lee

Dong-Yun Shin

Sung-Hee Lee

Sung-Hwan Park

Hye-Jin Son

Chul-Woo Yang

Jae-Kyung Kim

Jong-Young Choi

Eun-Kyung Kim

Hyeon-Beom Seo

Seung-Hun Lee

Jeong-Ho Lee

Chi-Hyun Cho

Ku-Chul Jung

Sang-Hyun Ryu

Ji-bum Moon

Chang Woo Lee

Eun-Ji Yang

Seung-Ki Kwok

Young-Mee Moon

Jin-Sil Park

Jin-Kwan Lee

Eun Kyung Kim

Young-sun Kim

Seung-dong Yu

Yoo-jin Choi

Chul-Woo Park

Chang-seog Ko

Keum-koo Lee

Woo-Yong Chang

Hyun-Joo Oh

Say Jang

Ji-young Kwahk

Young-shil Jang

Jung-won Lee

Ji-Su Jung

Dong-Seok Kim

Yeon-hee Roh

Eun-Jung Lee

Mi La Cho

Joo-Yeon Jhun

Joon-Hwan Kim

Soung-min Yoo

Yoon-ji Kim

Yoo-Jin Choi

Jung-Yeon Lim

Jae-yoon Ryu

Eun Ji Yang

Seok-Goo Cho

Hyun-Sil Park

Seong-Hyeok Park

Sahng-Hee Bahn

Keun-Hyung Cho

Se-Young Kim

Chui-Woo Park

Chul- Woo Yang

Yong-Gook Park

Seung-Hwan Hong

Bum-Joo Lee

The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone. Thus, the present invention may be used in the field of pharmaceutics relating to transplantation rejection or various immune disorders possibly occurring after transplantation.

Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor

The present disclosure relates to a method for inhibiting a STAT3 activity comprising administering SSu72 protein.

Method for inhibiting STAT3 activity comprising administering Ssu72

Disclosed is an electronic device including a battery; an interface that receives an external power; a system circuit including a processor; and a power management circuit, wherein the power management circuit is configured to detect an input of the external power through the interface; identify a voltage of the battery in response to the detection of the input of the external power; when the voltage of the battery belongs to a first designated voltage range, avoid charging the battery using the input external power and supply the input external power to the system circuit; and when the voltage of the battery belongs to a second designated voltage range, charge the battery using at least some of the input external power.

Charge control method and electronic device based on voltage of battery

The present disclosure relates to a method of preventing rheumatoid arthritis comprising administering a polynucleotide encoding Ssu72.

Method of preventing rheumatoid arthritis comprising administering polynucleotide encoding SSU72

The present invention relates to a cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory T-cells as an active ingredient. By infusing mesenchymal stem cells and immunoregulatory T-cells, which are the cellular therapeutic agent of the present invention, into bone marrow transplant animals, rejection to the host is suppressed after the engraftment of the transplanted bone-marrow to thus obtain the effect of reducing graft-versus-host disease and immune disease. Moreover, the effect of such GVHD reduction is much greater than the one obtained when only mesenchymal stem cells are infused. Accordingly, the cell therapy composition of the present invention having the above-mentioned effects can be useful in the prevention or treatment of immune disease.

Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient

The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-&#x3b1;, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.

Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient

Various embodiments relating to an electronic device and a method based on a battery leakage state have been described. According to an example embodiment, an electronic device includes a display; a communication circuit; a battery; a current sensor configured to measure a charge current used for charging the battery; and a processor, wherein the processor may be configured to measure a charge current using the current sensor, to determine a leakage state of the battery based on at least a part of the charge current, and to provide a notification corresponding to the leakage state through the display and/or perform a specified function corresponding to the leakage state based on at least a part of the leakage state.

Control method and electronic device based on battery leakage state

A metadata tagging system, an image searching method, a device, and a gesture tagging method are provided. The metadata tagging system includes a first device which tags metadata to an image and transmits the image tagged with the metadata and a second device which allows at least one image from among stored images to be searched. Accordingly, generated data may be searched and used more easily and conveniently.

Metadata tagging system, image searching method and device, and method for tagging a gesture thereof

Provided is a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present subject matter has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory T cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.

Compound having immune disease treatment effect and use thereof

Provided are a method and apparatus for displaying contents-related items. The method includes using a correlation between a first attribute and a second attribute to determine values of the second attribute, wherein the first attribute is one of a plurality of attributes of the contents-related items, the second attribute is one of a plurality of attributes of a plurality of blocks which is a part or a region of a screen, and each one of the plurality of blocks corresponds to each one contents-related item; and displaying the one or more contents-related items by displaying each corresponding block having the determined value of the second attribute on the screen, wherein the first attribute and the second attribute can be quantitatively represented.

Method and apparatus for displaying items related to contents

The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of IL-17 and TNF-&#x3b1;, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive T cells and increasing regulatory T cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the Mongolian medicinal plantor, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases.

Composition for treating immune diseases containing daurinol compound as active ingredient

Display screen or portion thereof with graphical user interface

Video graphical user interface for television receiver

Growing community of inventors

Incheon, South Korea

Min-Jung Park